Yang J Y, Schwartz A, Henderson E E
Department of Microbiology and Immunology, Temple University School of Medicine, Philadelphia 19140.
Biochem Biophys Res Commun. 1994 Jun 30;201(3):1424-32. doi: 10.1006/bbrc.1994.1862.
Human immunodeficiency virus type 1 (HIV-1) isolated from patients with acquired immunodeficiency syndrome (AIDS) shows resistance to 3'azido-3'deoxythymidine (AZT) after one or two years of treatment. AZT also has significant toxic side effects, further limiting its use in the therapy of HIV-1-infected individuals. Dehydroepiandrosterone (DHEA) has been shown to have a broad spectrum of biological functions, to be bioavailable orally and to be relatively nontoxic. Epidemiological studies provide evidence that reduced serum levels of DHEA are related to the progression of AIDS in HIV-1 infection. DHEA has also been shown to inhibit HIV-1 replication in vitro and block HIV-1 reactivation from chronically infected cell lines. However, there have been no reports on the ability of DHEA to inhibit the replication of AZT-resistant strains of HIV-1. We investigated whether DHEA treatment could inhibit replication of AZT-resistant strains of HIV-1. Addition of DHEA to MT-2 cell cultures infected with either AZT-sensitive or AZT-resistant isolates of HIV-1 resulted in dose-dependent inhibition of HIV-1-induced cytopathic effect and suppression of HIV-1 replication as measured by accumulation of reverse transcriptase activity. At a concentration as low as 50 microM, DHEA reduced AZT-resistant HIV-1 replication over 50 percent as measured by cytopathic effect and accumulation of reverse transcriptase activity. This study provides evidence that DHEA can inhibit the replication of AZT-resistant as well as wild-type HIV-1. Since the main targets for DHEA are metabolic and cellular signaling pathways leading to HIV-1 replication-activation, DHEA should be effective against multidrug-resistant strains of HIV-1. Combined with recently discovered immunoregulatory properties, the finding that DHEA is able to inhibit replication of both wild-type and AZT-resistant HIV-1 suggests that in vivo DHEA may have a much broader spectrum of action than originally anticipated.
从获得性免疫缺陷综合征(AIDS)患者中分离出的1型人类免疫缺陷病毒(HIV-1)在接受一两年治疗后会显示出对3'-叠氮-3'-脱氧胸苷(AZT)的耐药性。AZT也有显著的毒副作用,这进一步限制了其在治疗HIV-1感染个体中的应用。脱氢表雄酮(DHEA)已被证明具有广泛的生物学功能,可口服吸收且相对无毒。流行病学研究提供的证据表明,血清DHEA水平降低与HIV-1感染中AIDS的进展有关。DHEA还被证明在体外可抑制HIV-1复制,并阻止HIV-1从慢性感染的细胞系中重新激活。然而,尚无关于DHEA抑制HIV-1 AZT耐药株复制能力的报道。我们研究了DHEA治疗是否能抑制HIV-1 AZT耐药株的复制。将DHEA添加到感染了对AZT敏感或耐药的HIV-1分离株的MT-2细胞培养物中,会导致对HIV-1诱导的细胞病变效应产生剂量依赖性抑制,并通过逆转录酶活性的积累来衡量对HIV-1复制的抑制。在低至50微摩尔的浓度下,通过细胞病变效应和逆转录酶活性的积累来衡量,DHEA可使AZT耐药的HIV-1复制减少超过50%。这项研究提供的证据表明,DHEA可以抑制AZT耐药以及野生型HIV-1的复制。由于DHEA的主要靶点是导致HIV-1复制激活的代谢和细胞信号通路,DHEA应该对HIV-1的多药耐药株有效。结合最近发现的免疫调节特性,DHEA能够抑制野生型和AZT耐药HIV-1复制这一发现表明,在体内DHEA可能具有比最初预期更广泛的作用谱。